Our Chief Medical Officer Sheuli Porkess was privileged to contribute to this fantastic discussion, facilitated by John Rountree of Novasecta last month. Along with senior executives in the biotech and pharmaceutical sectors, the discussion explored the potential for AI to support Research and Development of new pharmaceutical interventions. A key area where the potential of AI has yet to be fully realised is the opportunity to help increase diversity of participation in clinical trials through identification of patient populations and cohorts that have high risk of disease progression, reflecting key co-morbidities. This is becoming possible, as it is across all the functions of pharmaceutical R&D, informed by real world patient, and health economic, data. A key takeaway from the discussion was that harnessing of AI's full potential requires an increasingly conscious cross-functional, multi-diciplinary approach to make this a reality - which Precisia Clinical Risk Analytics stands ready to support.
In March 2024, John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of AI for their R&D efforts. This report summarises insights from the workshop. With transparency, realism, and a truly multi-disciplinary and cross-functional mindset, AI has great potential in pharmaceutical R&D. The best is yet to come. Read more here: https://lnkd.in/e4su9hzh